Skip to content

Study on the clinical efficacy of Shi-Dan-Ke-Li in the treatment of chronic atrophic gastritis

Study on the clinical efficacy of Shi-Dan-Ke-Li in the treatment of chronic atrophic gastritis

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000145
Enrollment
Unknown
Registered
2024-07-30
Start date
2024-08-31
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic atrophic gastritis

Interventions

Shi-Dan-Ke-Li Group:Shi-Dan-Ke-Li + Wei-Fu-Chun simulant
Wei-Fu-Chun :Shi-Dan-Ke-Li simulant + Wei-Fu-Chun

Sponsors

Affiliated Hospital of Integrated Traditional Chinese and Western Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Meet the western medical diagnostic criteria for CAG (OLGA/OLGIM stage II and above). 2) Conforms to the Chinese medicine diagnosis of CAG of the weak spleen and stomach type (spleen and stomach cold deficiency syndrome). 3) Hp negative (at least one of C13 or C14 respiratory test is required) 4) Age 18-70 (including 18 and 70 years old), gender is not limited. 5) Voluntarily participate in this clinical trial, give informed consent and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1 Pregnant and lactating women 2 Endoscopy suggests gastric cancer and patients with pathologically confirmed gastric cancer, high-grade intraepithelial neoplasia, and severe heterogeneous hyperplasia. 3 Endoscopy suggests peptic ulcer patients. 4 Patients with poor adherence to medical advice or allergy to the drug. 5 Patients who cannot tolerate endoscopy 6 Patients with serious mental disorders who are unable to co-operate. 7 Patients with abnormalities in liver and kidney function and coagulation. 8Patients participating in another clinical study at the same time.

Design outcomes

Primary

MeasureTime frame
Pathological observation of stomach tissue;

Secondary

MeasureTime frame
PGII;G17;PGI;

Countries

China

Contacts

Public ContactHui Li

Affiliated Hospital of Integrated Traditional Chinese and Western Medicine

32260890@qq.com+8617601558686

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026